Annabelle Samimi
Analyst
Stiefel
Equibles does not estimate personal net worth.
About Annabelle Samimi
Annabelle Samimi is recorded as Analyst at Stiefel. Annabelle Samimi has spoken on 3 earnings calls across 3 companies, most recently for Phathom Pharmaceuticals, Inc. on October 29, 2026. Those appearances were for Phathom Pharmaceuticals, Inc. (PHAT), Mineralys Therapeutics, Inc. (MLYS) and REGENXBIO Inc. (RGNX). The companies whose calls Annabelle Samimi spoke on are classified in the Healthcare sector.
Annabelle Samimi on recent calls
“So first on the efforts for increasing BlinkRx, I guess in terms of getting past these frictions, where do you see the most resistance from physicians for adoption of Blink?”
“Just a little bit more on the commercial side. Maybe you can help. I know it's probably too early to talk about pricing, but is there any scenario where the competitor can angle for third line while you're putting yourself in fourth line first?”
“I'm going to be original and ask about 314. So, I noticed that you were moving forward with dose level 3, and I know also that you had agreed with Avi to conduct a phase 2 trial to test the higher dose, but you are going with dose level 3.”
Affiliation history
-
Stiefel
Analyst
Transcript header (unverified)
Current
Company network
REGENXBIO Inc.
RGNX
Biotechnology · Healthcare
1 appearance
Latest appearance 2026-03-05
View calls and events